// +author:k anargyrou +author:anargyrou 
var _ajax_res = {
  hits: 6,

  first: 0,

  results: [

{userid:"evangelos-briasoulis", "refid":"165","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"\"Real-world\" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma who were treated according to the standard clinical practice : a study of the Greek Myeloma Study Group","year":"2013","author":"E Katodritou, C Vadikolia, C Lalagianni, M Kotsopoulou, G Papageorgiou, M C Kyrtsonis, P Matsouka, N Giannakoulas, D Kyriakou, G Karras, N Anagnostopoulos, E Michali, E Briasoulis, E Hatzimichael, E Spanoudakis, P Zikos, A Tsakiridou, K Tsionos, K Anargyrou, A Symeonidis, A Maniatis, E Terpos","journal":"Ann Hematol","volume":"","number":"","pages":"","month":"","doi":"10.1007\/s00277-013-1841-y","pubmed":"","pdflink":"","urllink":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23892921","abstract":"Lenalidomide and dexamethasone (RD) is a standard of care for relapsed\/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition. We studied 212 RRMM patients who received RD in RW. Objective response (>\/=PR (partial response)) rate was 77.4 % (complete response (CR), 20.2 %). Median time to first and best response was 2 and 5 months, respectively. Median time to CR when RD was given as 2nd or >2nd-line treatment at 4 and 11 months, respectively. Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. Peripheral neuropathy was observed only in 2.5 % of patients and deep vein thrombosis in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial lenalidomide dose predicted for treatment discontinuation. Extra-medullary relapses occurred in 3.8 % of patients. Our study confirms that RD is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease.","note":"Katodritou, Eirini xD;Vadikolia, Chrysanthi xD;Lalagianni, Chrysavgi xD;Kotsopoulou, Maria xD;Papageorgiou, Georgia xD;Kyrtsonis, Marie-Christine xD;Matsouka, Panagiota xD;Giannakoulas, Nikolaos xD;Kyriakou, Despoina xD;Karras, Georgios xD;Anagnostopoulos, Nikolaos xD;Michali, Evridiki xD;Briasoulis, Evangelos xD;Hatzimichael, Eleftheria xD;Spanoudakis, Emmanouil xD;Zikos, Panagiotis xD;Tsakiridou, Anastasia xD;Tsionos, Konstantinos xD;Anargyrou, Konstantinos xD;Symeonidis, Argiris xD;Maniatis, Alice xD;Terpos, Evangelos xD;Ann Hematol. 2013 Jul 28.","tags":"","publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"","isi":"","key":"Katodritou2013","howpublished":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23892921"}
,

{userid:"evangelos-briasoulis", "refid":"170","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"\"Real-world\" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma who were treated according to the standard clinical practice : a study of the Greek Myeloma Study Group","year":"2014","author":"E Katodritou, C Vadikolia, C Lalagianni, M Kotsopoulou, G Papageorgiou, M C Kyrtsonis, P Matsouka, N Giannakoulas, D Kyriakou, G Karras, N Anagnostopoulos, E Michali, E Briasoulis, E Hatzimichael, E Spanoudakis, P Zikos, A Tsakiridou, K Tsionos, K Anargyrou, A Symeonidis, A Maniatis, E Terpos","journal":"Ann Hematol","volume":"93","number":"1","pages":"129-39","month":"","doi":"10.1007\/s00277-013-1841-y","pubmed":"","pdflink":"","urllink":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23892921","abstract":"Lenalidomide and dexamethasone (RD) is a standard of care for relapsed\/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition. We studied 212 RRMM patients who received RD in RW. Objective response (>\/=PR (partial response)) rate was 77.4 % (complete response (CR), 20.2 %). Median time to first and best response was 2 and 5 months, respectively. Median time to CR when RD was given as 2nd or >2(nd)-line treatment at 4 and 11 months, respectively. Quality of response was independent of previous lines of therapies or previous exposure to thalidomide or bortezomib. Median duration of response was 34.4 months, and it was higher in patients who received RD until progression (not reached versus 19 months, p < 0.001). Improvement of humoral immunity occurred in 60 % of responders (p < 0.001) and in the majority of patients who achieved stable disease. Adverse events were reported in 68.9 % of patients (myelosuppression in 49.4 %) and 12.7 % of patients needed hospitalization. Peripheral neuropathy was observed only in 2.5 % of patients and deep vein thrombosis in 5.7 %. Dose reductions were needed in 31 % of patients and permanent discontinuation in 38.9 %. Median time to treatment discontinuation was 16.8 months. Performance status (PS) and initial lenalidomide dose predicted for treatment discontinuation. Extra-medullary relapses occurred in 3.8 % of patients. Our study confirms that RD is effective and safe in RRMM in the RW; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease.","note":"Katodritou, Eirini xD;Vadikolia, Chrysanthi xD;Lalagianni, Chrysavgi xD;Kotsopoulou, Maria xD;Papageorgiou, Georgia xD;Kyrtsonis, Marie-Christine xD;Matsouka, Panagiota xD;Giannakoulas, Nikolaos xD;Kyriakou, Despoina xD;Karras, Georgios xD;Anagnostopoulos, Nikolaos xD;Michali, Evridiki xD;Briasoulis, Evangelos xD;Hatzimichael, Eleftheria xD;Spanoudakis, Emmanouil xD;Zikos, Panagiotis xD;Tsakiridou, Anastasia xD;Tsionos, Konstantinos xD;Anargyrou, Konstantinos xD;Symeonidis, Argiris xD;Maniatis, Alice xD;Terpos, Evangelos xD;eng xD;Germany xD;Ann Hematol. 2014 Jan;93(1):129-39. doi: 10.1007\/s00277-013-1841-y. Epub 2013 Jul 28.","tags":"","weight":170,"publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"","isi":"","key":"Katodritou2014","howpublished":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23892921"}
,

{userid:"eleftheria.hatzimichael", "articletype":"article","pages":"174-181","author":"Maria K Angelopoulou, Theodoros P Vassilakopoulos, Ioannis Batsis, Ioanna Sakellari, Konstantinos Gkirkas, Vasiliki Pappa, Panagiota Giannoulia, Ioannis Apostolidis, Christos Apostolopoulos, Paraskevi Roussou, Panayiotis Panayiotidis, Maria Dimou, Marie-Christine Kyrtsonis, Maria Palassopoulou, Georgios Vassilopoulos, Maria Moschogiannis, Christina Kalpadakis, Dimitrios Margaritis, Alexander Spyridonidis, Eurydiki Michalis, Konstantinos Anargyrou, Panagiotis Repousis, Eleutheria Hatzimichael, Zoi Bousiou, Elias Poulakidas, Dimitrios Grentzelias, Nikolaos Harhalakis, Gerassimos A Pangalis, Achilles Anagnostopoulos, Panagiotis Tsirigotis","year":"2018","title":"Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma. The Hellenic experience.","month":"Feb","journal":"Hematological oncology","publisher":"","volume":"36","number":"1","note":"","tags":"Adult,Female,Hodgkin Disease,Humans,Immunoconjugates,Male,Prognosis,Retrospective Studies,Survival Analysis,Treatment Outcome","booktitle":"","editor":"","abstract":"This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed\/refractory (R\/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety-five patients with R\/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33\u00a0years, and 62% were males. Sixty-seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age\/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2-16), and the median time to best response was the fourth cycle. Fifty-seven patients achieved an objective response: twenty-two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty-six (27%) had progressive disease as their best response. At a median follow-up of 11.5\u00a0months, median progression-free survival and overall survival were 8 and 26.5\u00a0months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P\u00a0=\u00a0.005). Bulky disease (P\u00a0=\u00a0.01) and response to BV (P\u00a0<.001) were significant for progression-free survival, while refractoriness to most recent treatment (P\u00a0=\u00a0.04), bulky disease (P\u00a0=\u00a0.005), and B-symptoms (P\u00a0=\u00a0.001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow-up of 13\u00a0months. In conclusion, our data indicate that BV is an effective treatment for R\/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen.","address":"","school":"","issn":"1099-1069","doi":"10.1002\/hon.2383","isi":"","pubmed":"28219112","key":"Angelopoulou2018","howpublished":"","urllink":"","refid":"100","weight":"100"}
,

{userid:"eleftheria.hatzimichael", "refid":"126","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.","year":"2021","author":"Theodoros P Vassilakopoulos, Michail Michail, Sotirios Papageorgiou, Georgia Kourti, Maria K Angelopoulou, Fotios Panitsas, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Evangelos Terpos, Maria N Dimopoulou, Stamatios Karakatsanis, Eurydiki Michalis, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Theophanis Economopoulos, Lydia Kyriazopoulou, Marina P Siakantaris, Marie-Christine Kyrtsonis, Argyris Symeonidis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Hatjiharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Gabriella Gainaru, Ekaterini Stefanoudaki, Panayiotis Zikos, Panayiotis Tsirigotis, Gerasimos Tsourouflis, Theodora Assimakopoulou, Pavlina Konstantinidou, Helen A Papadaki, Katerina Megalakaki, Meletios-Athanasios Dimopoulos, Vassiliki Pappa, Themis Karmiris, Paraskevi Roussou, Panayiotis Panayiotidis, Kostas Konstantopoulos, Gerassimos A Pangalis","journal":"The oncologist","volume":"26","number":"7","pages":"597-609","month":"07","doi":"10.1002\/onco.13789","pubmed":"33870594","pdflink":"","urllink":"","abstract":"R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions.","note":"","tags":"Adult,Antineoplastic Combined Chemotherapy Protocols,Cyclophosphamide,Doxorubicin,Humans,Lymphoma, Large B-Cell, Diffuse,Prednisone,Prognosis,Rituximab,Vincristine","weight":126,"publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1549-490X","isi":"","key":"Vassilakopoulos2021","howpublished":""}
,

{userid:"eleftheria.hatzimichael", "refid":"129","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.","year":"2021","author":"Theodoros P Vassilakopoulos, Sotirios G Papageorgiou, Maria K Angelopoulou, Sophia Chatziioannou, Vassilios Prassopoulos, Stamatios Karakatsanis, Maria Arapaki, Zois Mellios, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Evangelos Terpos, Evridiki Michali, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Marina P Siakantaris, Marie-Christine Kyrtsonis, Argyris Symeonidis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Chatziharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Gabriella Gainaru, Catherine Mainta, Panagiotis Tsirigotis, Theodora Assimakopoulou, Pavlina Konstantinidou, Helen Papadaki, Meletios-Athanassios Dimopoulos, Vassiliki Pappa, Themis Karmiris, Paraskevi Roussou, Ioannis Datseris, Panayiotis Panayiotidis, Kostas Konstantopoulos, Gerassimos A Pangalis, Phivi Rondogianni","journal":"Annals of hematology","volume":"100","number":"9","pages":"2279-2292","month":"Sep","doi":"10.1200\/JCO.19.01492","pubmed":"33523289","pdflink":"","urllink":"","abstract":"End-of-treatment (EoT) PET\/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the prognostic significance of EoT-PET\/CT after adequate response to R-CHOP. Among 231 consecutive PMLBCL patients, 182 underwent EoT-PET\/CT and were evaluated according to the Deauville 5-point scale (D5PS) criteria. Freedom from progression (FFP) was measured from the time of PET\/CT examination. Among 182 patients, 72 (40%) had D5PS score 1 (D5PSS-1), 33 (18%) had 2, 28 (15%) had 3, 29 (16%) had 4, and 20 (11%) had 5. The 5-year FFP was 97, 94, 92, 82, and 44% for D5PSS-1, D5PSS-2, D5PSS-3, D5PSS-4, and D5PSS-5, respectively. Among 105 patients with unequivocally negative PET\/CT (D5PSS-1\/D5PSS-2), 49 (47%) received RT (median dose 3420 cGy) and 56 (53%) did not with relapses in 0\/49 vs. 4\/56 patients (2 mediastinum and 2 isolated CNS relapses).The 5-year FFP for those who received RT or not was 100% versus 96%, when isolated CNS relapses were censored (p = 0.159). Among D5PSS-3 patients (27\/28 irradiated-median dose 3600 cGy), the 5-year FFP was 92%. The 5-year FFP for D5PSS-4 and D5PSS-5 was 82 and 44%; 44\/49 patients received RT (median dose 4000 and 4400 cGy for D5PSS-4 and D5PSS-5). Our study supports the omission of RT in a sizeable fraction of PET\/CT-negative patients and definitely discourages salvage chemotherapy and ASCT in patients with PMLBCL who conventionally respond to R-CHOP, solely based on PET\/CT positivity in the absence of documented progressive or multifocal disease. The persistence of positive PET\/CT with D5PSS < 5 after consolidative RT should not trigger the initiation of further salvage chemotherapy in the absence of conventionally defined PD.","note":"","tags":"Adolescent,Adult,Aged,Antineoplastic Combined Chemotherapy Protocols,Cyclophosphamide,Doxorubicin,Female,Humans,Lymphoma, Large B-Cell, Diffuse,Male,Mediastinal Neoplasms,Middle Aged,Positron Emission Tomography Computed Tomography,Prednisone,Retrospective Studies,Rituximab,Treatment Outcome,Vincristine,Young Adult","weight":129,"publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1432-0584","isi":"","key":"Vassilakopoulos2021","howpublished":""}
,

{userid:"eleftheria.hatzimichael", "refid":"133","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.","year":"2022","author":"Stamatis J Karakatsanis, Maria Bouzani, Argyris Symeonidis, Maria K Angelopoulou, Sotirios G Papageorgiou, Michail Michail, Gabriella Gainaru, Georgia Kourti, Sotirios Sachanas, Christina Kalpadakis, Eirini Katodritou, Theoni Leonidopoulou, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Kotsopoulou, Maria Dimou, Eleni Variamis, Dimitrios Boutsis, Nick Kanellias, Maria N Dimopoulou, Evridiki Michali, George Karianakis, Pantelis Tsirkinidis, Chryssa Vadikolia, Christos Poziopoulos, Anna Pigaditou, Effimia Vrakidou, Theophanis Economopoulos, Lydia Kyriazopoulou, Marina P Siakantaris, Marie-Christine Kyrtsonis, Konstantinos Anargyrou, Maria Papaioannou, Evdoxia Hatjiharissi, Elissavet Vervessou, Maria Tsirogianni, Maria Palassopoulou, Ekaterini Stefanoudaki, Panayiotis Zikos, Panayiotis Tsirigotis, Gerassimos Tsourouflis, Theodora Assimakopoulou, Evgenia Verrou, Helen Papadaki, Polixeni Lampropoulou, Meletios-Athanasios Dimopoulos, Vassiliki Pappa, Kostas Konstantopoulos, Themis Karmiris, Paraskevi Roussou, Panayiotis Panayiotidis, Gerassimos A Pangalis, Theodoros P Vassilakopoulos,  ","journal":"In vivo (Athens, Greece)","volume":"36","number":"3","pages":"1302-1315","month":"May\/Jun","doi":"10.21873\/invivo.12831","pubmed":"35478115","pdflink":"","urllink":"","abstract":"Primary mediastinal large B-cell lymphoma (PMLBCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody rituximab into current therapeutic regimens. Evidence, however, on the optimal time interval between consecutive chemoimmunotherapy (CIT) cycles is still scarce. This study aimed to evaluate the efficacy outcomes of the more commonly administered 3-weekly regimens to the biweekly ones in a PMLBCL patients' population, who were mostly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP-21) or R-CHOP-14.","note":"","tags":"Antineoplastic Combined Chemotherapy Protocols,Cyclophosphamide,Doxorubicin,Humans,Lymphoma, B-Cell,Prednisone,Prospective Studies,Retrospective Studies,Rituximab,Vincristine","weight":133,"publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1791-7549","isi":"","key":"Karakatsanis2022","howpublished":""}
  ]
}

;
ajaxResultsLoaded(_ajax_res);